Mankind Pharma Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.0L Cr
Mankind Pharma aims for sustainable long-term growth, focusing on solid foundations and efficiency improvements. BSV business margins expected to improve by ~100 bps annually over next 2-3 years, targeting 30% margins in 5 years.
From Mankind Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,384
Market Cap
₹1.0L Cr
P/E Ratio
47.0
How does Mankind Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare Mankind Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Mankind Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.4K Cr, net profit ₹559 Cr.
Full financials →📊 Revenue & Sales Performance
- →Mankind Pharma aims for sustainable long-term growth, focusing on solid foundations and efficiency improvements.
- →Organic domestic growth is expected to continue, with Q3 FY25 showing 8.4% domestic growth and 43% export growth.
- →Chronic segment is growing faster and gaining share, currently at 37.6% of sales, up 200 bps YoY.
- →BSV business integration is underway with expectations of a flat to single-digit growth in FY25; post restructuring, growth should recover.
- →The company targets 15%+ growth for BSV portfolio over the next two years, driven by high entry barriers and specialty products.
- →Margins are expected to improve gradually by about 100 bps annually over the next 2-3 years, aiming for 30% margins in BSV.
- →Corrective measures in field force and leadership reshuffling are ongoing to drive productivity, with most changes nearing completion.
📈 Profitability & Margins
- →BSV business margins expected to improve by ~100 bps annually over next 2-3 years, targeting 30% margins in 5 years.
- →EBITDA margins have increased due to corrective actions and are expected to sustain improvements.
- →Corrective actions in field force and management led to improved efficiency, margins, and foundation for growth despite short-term growth impact.
- →Organic domestic and export growth remain strong, with export growing 43% YoY in Q3 FY25 and 53% in 9M FY25.
- →Chronic segment growing faster than acute, with chronic share rising to 37.6% of total sales, driving better profitability.
- →Net debt to adjusted EBITDA target set at 2x by year-end to maintain financial discipline.
- →Long-term vision includes steady base business, fast-growing specialty chronic segment, OTC expansion, and high entry barrier super-specialty portfolio driving sustainable earnings growth.
- →Corrective actions and new leadership infusion expected to support consistent margin improvement and EPS growth.
🏗️ Capital Expenditure Plans
- →Capex spends for 9M FY'25 were INR344 crores, which is 3.7% of total revenue, aligning with guidance of 4%-5%.
- →Strategic investments include the acquisition of BSV to expand into high entry barrier portfolios and specialty R&D tech platforms.
- →The company raised INR10,000 crores through NCDs and CPs for the BSV acquisition and INR3,000 crores in equity used to repay CPs, showing financial discipline.
- →Future investments include ongoing R&D initiatives to enter semi-regulated and regulated markets, supporting margin improvement in BSV business.
- →Integration and synergies from the BSV acquisition (expected INR50-100 crores benefit over 12-24 months) involve procurement optimization, portfolio rationalization, field force productivity, and cross-selling opportunities.
- →Capex guidance remains around 4%-5% of revenue, indicating continued focus on capital investments for growth.
💰 Fundraising & Capital Structure
- →Mankind Pharma raised INR10,000 crores through NCDs and CPs for the acquisition of BSV.
- →Additionally, INR3,000 crores was raised via equity and used to repay a portion of CPs as of January 16, 2025.
- →There was no mention of any new or upcoming fundraising plans through debt or equity in the latest call.
- →The company emphasized maintaining a healthy financial position with a focus on reducing net debt to adjusted EBITDA to 2x by year-end.
- →Current net debt to adjusted EBITDA stands at 2.2x as of the quarter-end.
- →No explicit plans for fresh fundraising were disclosed; focus remains on integration, corrective actions, and financial discipline.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Mankind Pharma Ltd Q3 FY25 results?
Mankind Pharma aims for sustainable long-term growth, focusing on solid foundations and efficiency improvements. BSV business margins expected to improve by ~100 bps annually over next 2-3 years, targeting 30% margins in 5 years.
What is Mankind Pharma Ltd share price analysis?
Mankind Pharma Ltd currently shows a neutral. The stock trades at a P/E of 47.0 with a market cap of ₹100,160 Cr. Investors should review the full earnings analysis for detailed insights.
Is Mankind Pharma Ltd planning capital expenditure?
Capex spends for 9M FY'25 were INR344 crores, which is 3.7% of total revenue, aligning with guidance of 4%-5%.
Keep Mankind Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.